Health

The Role of Technology in Driving Affordable Healthcare

Published

4 years ago

August 19, 2022

Brillio CTO Chander Damodaran Shares Some Promising Trends in Healthcare Market Dynamics

If any event could cause a massive upheaval within the healthcare industry, it would be a global pandemic. COVID-19 forced institutions and practitioners to reevaluate their methods and internal systems from top to bottom. Technology, telecommunications, and consumer industries pivoted their attention towards the healthcare industry looking to address new challenges and disruptions caused and revealed by the pandemic. Telehealth, in particular, saw a massive increase in interest and funding from these sectors as the global pandemic accelerated the need for digital solutions.

At digital tech companies like Brillio, team members search for solutions to the challenges faced by patients and practitioners alike. Their team is focused on developing forward-thinking, real-world tech to meet the growing public demand for better, more efficient healthcare. According to Brillio’s data, the global healthcare IT market is projected to grow 29.3% within the next 8 years reaching a value of $135.6 billion. The telehealth revenue share in the global healthcare IT alone is anticipated to grow at a rate of 41%, the fastest growth rate ever recorded.

According to the CTO of Brillio Chander Damodaran, the market is becoming vastly more patient-centric. For digital tech companies, the time is opportune to develop technology solutions that can benefit the average patient. Most of us are pretty comfortable with wearable technology- think Apple Watch or Fitbit for example- but there is massive potential to digitize all of the different systems including wearables to create a truly connected digital experience. Tech that monitors and shares health parameters is nothing new, and it could be just the beginning. Telehealth is poised to bring patients and providers closer than ever before, if not physically, then certainly virtually. Damodaran predicts a swift increase in the utilization of telehealth services of 38% post-pandemic as health systems weave digital solutions into their institutional systems.

In his opinion, there is a massive demand for telehealth solutions that benefit consumers by making pricing and procedural information more transparent. One way this is manifesting is through the emergence of mandates from the Centers for Medicare & Medicaid Services (CMS) and the Office of National Statistics. These mandates, including the CMS Interoperability and Patient Access Final Rule published in May 2020 and the CMS Price Transparency Final Rule published in July 2022, would allow patients to make an informed decision on their providers and services thus offering greater control over their healthcare plans and spending.

Damodaran is optimistic about where the industry is headed in relation to digital tech. From venture capital to private investment, investment in telehealth is booming. Increased interest in tech solutions for the healthcare industry is driving up investment rates, allowing for more development. This could result in better immersive and wearable technologies, the acceleration of solutions like digital twins, and the development of new tech solutions.

While many are still trying to understand the extent of their healthcare costs, increased accessibility and transparency remain at the forefront of the conversation. All these trends are not only exciting developments for the tech world and interesting opportunities for investors, but they are also potentially life-changing developments for each one of us leading to affordable healthcare and access to globally renowned experts and practitioners.

For more information about the role of technology in healthcare, visit www.brillio.com.

Health

BioLongevity Labs: How Two Biohackers Are Making Longevity Safe for the Mainstream

Published

17 hours ago

February 18, 2026

Michelle Langton

Humans have been looking for ways to extend their lifespan for hundreds of years. Medicine has made impressive strides, but for many, the effects of aging are still painfully real.

Through BioLongevity Labs, biohackers and entrepreneurs Jay Campbell and Josh Felber aim to introduce ordinary people to potentially life-changing compounds called peptides. Campbell and Felber come from very different backgrounds.

Campbell is a five-time international bestselling author and globally recognized leader in the health-optimization space. Felber is a serial entrepreneur who excels at scaling businesses.

For both men, BioLongevity Labs is more than just a business venture — it’s about helping everyday people discover something that just might prolong and improve their lives.

“Your body inevitably changes as the years pile on,” says Campbell. “Your energy drops, and wrinkles start showing up uninvited. Peptides can change everything.”

Many people have probably heard the term “peptide” in passing. Some may know they’re associated with longevity. Most people just don’t have a strong grasp of how they work.

A peptide is a short chain of amino acids, which are the building blocks of proteins. Essentially, peptides are like shorter, simpler proteins. That might sound unremarkable, but the real magic of peptides lies in how they work.

They function as signaling or “messenger” molecules telling the body to perform specific functions. Many peptides function similarly to hormones. A relevant example is GLP-1 (glucagon-like peptide-1) receptor agonists. This class of medications includes semaglutide and tirzepatide, two wildly popular weight-loss drugs.

“These peptides aren’t just another biohacking fad,” Campbell explains. “They enhance insulin secretion and suppress glucagon release to balance blood sugar levels and promote sustainable weight loss”. But what sets GLP-1 receptor agonists apart is their ability to regulate hunger.

Through the reduction of appetite and increased feelings of fullness, it is far easier for dieters to stick to a calorie deficit.” Although GLP-1 receptor agonists are widely prescribed, most peptides aren’t.

Campbell asserts, because many peptides have the potential to cure illnesses by treating the fundamental root cause, they go against America’s “sick care” model of healthcare. They potentially threaten drug companies and their bottom line.

“Peptides are simultaneously a dream come true for mankind and the worst possible nightmare for the pharmaceutical industry,” says Campbell. “It’s not a conspiracy theory. It’s pure economics and psychology in action. People will do whatever it takes to make as much money as possible in a free-market society, even if it means suppressing a superior solution.”

Patients probably aren’t going to be introduced to peptides through the healthcare system. Many discover them on their own. But for the many people who don’t have a solid understanding of how they work molecularly or even what dose to take, there is a risk. That’s precisely what BioLongevity Labs’ co-founders are attempting to address.

Jay Campbell has dedicated his life to educating people about therapeutic peptides and optimized hormones, and along with his partner Josh Felber, they’ve created a company offering filler-free, third-party tested peptides and bioregulators.

Campbell and Felber stress the fact that BioLongevity Labs isn’t meant to be a replacement for traditional medical care. Instead, its products bridge the gap between clinical and extra-clinical care. There’s no magic pill or single solution to solve the problem of aging.

But thanks to the development of specialized peptides, bioregulators, and small molecules, we’re closer than we’ve ever been before.